2026-04-27T14:40:43Zhttps://uvadoc.uva.es/oai/request

oai:uvadoc.uva.es:10324/616022025-01-09T11:51:06Zcom_10324_1179com_10324_931com_10324_894col_10324_1306

Influence of non-osteoporotic treatments in patients on active anti-osteoporotic therapy: evidence from the OSTEOMED registry Coco Martín, María Begoña Leal Vega, Luis Blázquez Cabrera, José Antonio Navarro, Amalia Moro, María Jesús Arranz García, Francisca Amérigo, María José Sosa Henríquez, Manuel Vázquez, María Ángeles Montoya, María José Díaz Curiel, Manuel Olmos, José Manuel Ruiz Mambrilla, Marta María Filgueira Rubio, José Pérez Castrillon, José Luis Hernández de Sosa, Nerea Calero Bernal, María Luz Armengol Sucarrats, Dolors Escalante Yanguas, Begoña de Miranda Díaz, Cristina Miranda García, María José Giner García, Mercedes Jareño Chaumel, Julia Cotos Canca, Rafael Hernández, José Luis Rodero Hernández, Francisco Javier Sánchez Molini, Pilar Aguado Caballero, José María Cobeta García, Juan Carlos Tirado Miranda, Raimundo Purpose To evaluate the effect of different non-osteoporotic drugs on the increase or decrease in the risk of incident fragility fractures (vertebral, humerus or hip) in a cohort of patients diagnosed with osteoporosis on active anti-osteoporotic therapy. Methods For this retrospective longitudinal study, baseline and follow-up data on prescribed non-osteoporotic treatments and the occurrence of vertebral, humerus or hip fractures in 993 patients from the OSTEOMED registry were analyzed using logistic regression models. The drugs evaluated with a possible beneficial effect were thiazides and statins, while the drugs evaluated with a possible harmful effect were antiandrogens, aromatase inhibitors, proton pump inhibitors, selective serotonin reuptake inhibitors, benzodiazepines, GnRH agonists, thyroid hormones, and oral and inhaled corticosteroids. Results Logistic regression analyses indicated that no treatment significantly improved fracture risk, with the only treatments that significantly worsened fracture risk being letrozole (OR = 0.18, p-value = 0.03) and oral corticosteroids at doses ≤ 5 mg/ day (OR = 0.16, p-value = 0.03) and > 5 mg/day (OR = 0.27, p-value = 0.04). Conclusion The potential beneficial or detrimental effects of the different drugs evaluated on fracture risk are masked by treatment with anabolic or antiresorptive drugs that have a more potent action on bone metabolism, with two exceptions: letrozole and oral corticosteroids. These findings may have important clinical implications, as patients receiving these treat- ments are not fully protected by bisphosphonates, which may imply the need for more potent anti-osteoporotic drugs such as denosumab or teriparatide. 2023-09-18T08:08:24Z 2023-09-18T08:08:24Z 2023-09-18T08:08:24Z 2023 info:eu-repo/semantics/article European Journal of Clinical Pharmacology, 2023, vol. 79, n. 10, p. 1333-1339. 0031-6970 https://uvadoc.uva.es/handle/10324/61602 10.1007/s00228-023-03544-x 1333 10 1339 European Journal of Clinical Pharmacology 79 1432-1041 eng https://link.springer.com/article/10.1007/s00228-023-03544-x info:eu-repo/semantics/openAccess http://creativecommons.org/licenses/by/4.0/ © 2023 The Author(s) Atribución 4.0 Internacional Springer